Save information for later
Sign Up

Learn About Gliomatosis Cerebri

View Main Condition: Brain Tumor

What is the definition of Gliomatosis Cerebri?
Gliomatosis cerebri is a type of malignant (cancerous) brain tumor called a glioblastoma that develops from a specific type of brain cell called an astrocyte. It involves at least three sections (lobes) within the main part of the brain (cerebrum). It may also affect both sides of the cerebrum as well as the nerve cells within the brain (grey matter). There are two types of Gliomatosis cerebri. Type 1 (classic form) is characterized by scattered and widespread tumor cells and no apparent mass or tumor, while type 2 has similar characteristics in addition to a detectable mass or tumor. Signs and symptoms of Gliomatosis cerebri may include personality changes, memory disturbance, headaches, and seizures.
What are the alternative names for Gliomatosis Cerebri?
  • Gliomatosis cerebri
Who are the top Gliomatosis Cerebri Local Doctors?
Hematology Oncology | Hematology | Oncology
Hematology Oncology | Hematology | Oncology

South Carolina Cancer Specialists

100 Buckwalter Place Blvd, Suite 130, 
Bluffton, SC 
 10.4 mi
Accepting New Patients

Majd Chahin is a Hematologist Oncology specialist and a Hematologist in Bluffton, South Carolina. Dr. Chahin and is rated as an Experienced provider by MediFind in the treatment of Gliomatosis Cerebri. His top areas of expertise are Myelodysplastic Syndrome (MDS), Paget Disease of the Breast, Breast Cancer, and Colorectal Cancer. Dr. Chahin is currently accepting new patients.

Pediatric Hematology Oncology | Pediatrics | Hematology Oncology
Pediatric Hematology Oncology | Pediatrics | Hematology Oncology
4700 Waters Ave, 
Savannah, GA 
 23.6 mi
Accepting New Patients

Andrew Pendleton is a Pediatric Hematologist Oncology specialist and a Pediatrics provider in Savannah, Georgia. Dr. Pendleton and is rated as an Experienced provider by MediFind in the treatment of Gliomatosis Cerebri. His top areas of expertise are Ependymoma, Histiocytosis, Reticulohistiocytoma, Hepatoblastoma, and Bone Marrow Aspiration. Dr. Pendleton is currently accepting new patients.

 
 
 
 
Learn about our expert tiers
Learn More
Radiation Oncology
Radiation Oncology

Coastal Cancer Care, LLC

4700 Waters Ave, 
Savannah, GA 
 23.6 mi
Accepting New Patients
Offers Telehealth

Michael Hasselle is a Radiation Oncologist in Savannah, Georgia. Dr. Hasselle and is rated as an Experienced provider by MediFind in the treatment of Gliomatosis Cerebri. His top areas of expertise are Lung Cancer, Atypical Teratoid Rhabdoid Tumor (ATRT), Neuroepithelioma, Ependymoma, and Gamma Knife Radiosurgery. Dr. Hasselle is currently accepting new patients.

What are the latest Gliomatosis Cerebri Clinical Trials?
A Phase 0/1 Study of BDTX-1535 in Recurrent High-Grade Glioma (HGG) Participants with EGFR Alterations or Fusions Scheduled for Resection to Evaluate Central Nervous System (CNS) Penetration with PK-triggered Expansion Cohort

Summary: This study will administer the investigational drug, BDTX-1535 to eligible patients with recurrent high-grade glioma. BDTX-1535 was designed to block a growth signal important to some cancers. BDTX-1535 is being tested in this study to see if it can be given safely to people who have tumors that can be dependent on that growth signal because of changes in a protein called EGFR. These gene changes ...

Match to trials
Find the right clinical trials for you in under a minute
Get started
Lomustine With and Without Reirradiation for First Progression of Glioblastoma: a Randomized Phase III Study

Summary: Despite comprehensive multimodal treatment of newly diagnosed glioblastoma, almost all patients suffer from tumour relapse. Currently, no standard of care exists to treat these tumour relapses. Treatment options include repeated surgery (if feasible), systemic therapy (bevacizumab, lomustine, temozolomide re-challenge), reirradiation and best supportive care. Currently, the superiority of combined...

Who are the sources who wrote this article ?

Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center